Curatis Holding AG Secures CHF 3.0 Million from Swiss Investor

Curatis Holding AG, a company listed on the SIX Swiss Exchange, announced a CHF 3.0 million private placement with a Swiss strategic investor. The investment, structured as a convertible instrument, affords the investor future conversion into company shares, sourced from Curatis' conditional capital.

This capital influx is aligned with prevailing market conditions and will be finalized once customary closing protocols are met. The funds will drive forward the clinical development of corticorelin, the company's leading candidate. This includes preparing for Phase III studies in Japan and globally, ensuring a smooth path towards broader clinical applications.

Curatis is committed to advancing treatments for rare diseases, boasting a portfolio of over 40 products. This financial agreement reflects a strategic step towards their mission.